Biotx.ai
The AI engine Fit Assessment
BetaBiotx.ai leverages machine learning for pattern discovery and therapeutic expansion, while also focusing on biomarker identification for precision medicine.
Blurb
Biotx.ai delivers next-generation biomarkers as a basis for decision support in precision medicine.
HQ Location
Germany
Founded
2017
Employees
1 - 10
Total funding raised
Not available
Last Funding Event
Convertible Note, April 5, 2023
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Biomarker Identification
Developer of a drug discovery platform designed to identify significant patterns for developing novel diagnostics and therapies. The company's platform effectively monitors individual responses like artificial neural networks to stratify patients in clinical studies and develop new drugs, enabling physicians to overcome unmet medical needs.